EVENITY® Risk Minimisation Materials Effectiveness Measurement in Australia (20220120)

Study type

• Study type:
  Non-interventional study
• Scope of the study:
  Effectiveness study (incl. comparative)

Non-interventional study

• Non-interventional study design:
  Other
• Non-interventional study design, other:
  Study of responses to questionnaires on educational materials by medical professionals in Australia

Study drug and medical condition

• Name of medicine:
  Evenity
• Study drug International non-proprietary name (INN) or common name:
  ROMOSOZUMAB
• Anatomical Therapeutic Chemical (ATC) code:
  200000003495

  romosozumab

Population studied

• Age groups:
  Adult and elderly population (>18 years)

  Adults (18 to < 65 years)

  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Elderly (≥ 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Estimated number of subjects:
  765

Study design details

• Main study objective:
  The objective of this study is to measure the effectiveness of prescriber guide and patient alert card on awareness, utilization and adequacy targeted to HCPs in addressing the cardiovascular risks (myocardial infarction and stroke).
• Outcomes:
  Measure awareness of the educational materials, identify if specialists distribute the educational materials to their patients and/or caregivers when prescribing EVENITY, determine adequacy of the content of the education materials.
• Data analysis plan:
  A market research vendor will conduct a survey to assess the effectiveness of the educational materials provided to Specialists. This survey will consist of a questionnaire targeted to Endocrinologists, Rheumatologists, Geriatricians and General Physicians in Australia who can prescribe EVENITY to patients. Study results will be in tabular form and aggregate analyses that omits subject identification.

Documents

Study report

20220120_ORSR_Abstract_Redacted.pdf